The Form 4 filing was filed on November 9, 2026. This SEC form reports changes in an insider's company stock holdings. The sales took place from November 5 through November 9, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-05 |
| Date of Latest Transaction | 2026-11-09 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 43,643 |
| Price | $35.60 |
| Total Transaction Value | $1,553,753.61 |
| Insider | |
| Ticker Symbol | PGNY |
| Company | Progyny, Inc. |
| Insider Name | Anevski Peter |
| Insider Title | CHIEF EXECUTIVE OFFICER |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 762,468 |
| Position Size Change | 5.41% |
| Filing | |
| Filing Date | 2026-11-09 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
Peter Anevski, CEO of Progyny, Inc. (PGNY), reported two share sales. They carry transaction code S, which identifies sales. The two transactions are grouped in one Form 4 filing.
What was the average price of the transaction?
The average price was $35.60 per share across the two sales, rounded to cents. The available details do not include separate share counts or prices for each sale.
How did this transaction affect the insider's holdings?
Peter Anevski sold 43,643 shares and reported 762,468 shares owned afterward. The sales accounted for 5.41% of the shares he held before the sales.
What's the total transaction value?
The two sales had a total reported value of $1,553,753.61, rounded to cents. This amount covers all 43,643 shares sold across both transactions.
Are there any special circumstances around this transaction?
The filing information includes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. A reference can apply to an entire filing without showing which sales used the plan. The available details do not show whether it covers one sale or both. Footnote text and plan terms are not available. The plan's start date and trading schedule are unknown.
For research purposes only; not investment advice.